TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02780479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: at 24 hours from the first Dexamethasone dose given in ED.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: at 24 hours from the first Dexamethasone dose given in ED.
Study: NCT05118542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propylthiouracil
Description: PTU were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: methimazole were given to participants with adjusted dosage according to patient clinical assessment at every visit by their own endocrinologist.
Study: NCT04031404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse TMS
Description: Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse TMS
Description: Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
Study: NCT03645889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLTG
Description: A combination of 13 herbal granules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 90% starch filler and 10% PLTG
Study: NCT03956888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
Study: NCT03330600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aquatic physicotherapy
Description: Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aquatic physicotherapy
Description: Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: immersion
Description: The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: immersion
Description: The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
Study: NCT02014727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A1 : 50µg AMA1-DiCo + Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A2 : 50 µg AMA1-DiCo+ GLA-SE

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A2 : 50 µg AMA1-DiCo+ GLA-SE

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Group B2 : Placebo
Study: NCT00799500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Weekly vaginal pH
Study: NCT04291976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back-to-back high-definition white light endoscopy
Description: Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached, with a second segmental inspection after the first examination in the same session.The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-pass high-definition white light endoscopy
Description: Using HD white light, the entire colon is examined for dysplasia and other abnormalities after the caecum is reached. The colonoscope has a high-definition camera and processor. All images are displayed on a high definition monitor for optimal resolution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chromoendoscopy
Description: After introduction of the endoscope into the colon a dye (methylene blue or indigo carmine) will be sprayed through a catheter positioned into the biopsy channel. Per segment, the entire colon is dyed, inspected, and lesions are removed. Equipment is similar to the other two interventions.
Study: NCT01444313

Intervention type: DEVICE
Group type: OTHER
Intervention: narafilcon A contact lens
Description: Soft contact lenses with UV protection

Intervention type: DEVICE
Group type: OTHER
Intervention: narafilcon A contact lens
Description: Soft contact lenses with UV protection

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A soft contact lenses
Description: Soft contact lenses without UV protection

Intervention type: DEVICE
Group type: OTHER
Intervention: nelfilcon A soft contact lenses
Description: Soft contact lenses without UV protection
Study: NCT03608891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided patient specific 3D titanium plate
Description: CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional titanium miniplates
Description: In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
Study: NCT01273389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 136
Description: Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
Study: NCT03568812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rillus®
Description: Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
Study: NCT01014702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LensAR Laser System
Description: Use of laser for capsulotomy and lens fragmentation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phacoemulsification
Description: Use of standard techniques for capsulotomy and lens fragmentation
Study: NCT01922245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS
Description: Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
Study: NCT03602261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcifediol Oral Capsule
Description: Capsule, weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcifediol Oral Capsule
Description: Capsule, weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcifediol Oral Capsule
Description: Capsule, weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule, weekly
Study: NCT00801853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerovant
Description: Aerovant 1mg bid (dry powder)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerovant
Description: Aerovant 3mg bid (dry powder)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerovant
Description: Aerovant 10mg bid (dry powder)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control (dry powder)
Study: NCT03852914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 2%
Description: Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
Study: NCT00433446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 328
Study: NCT03744130

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound
Description: 1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound
Description: 1. administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~2. visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~3. administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~4. the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~5. the original DICOM loop is sent to a work station
Study: NCT01640990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 30mins run-in period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 30mins run-in period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW328267X (total dose of 12mcg)
Description: 8 mcg/h for 1.5 hours (total dose of 12mcg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW328267X (total dose of 40mcg)
Description: 10 mcg/h for 4 hours (total dose of 40 mcg)
Study: NCT02310906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SRP-4053 placebo-matching solution for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4053
Description: SRP-4053 (golodirsen) solution for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-4053
Description: SRP-4053 (golodirsen) solution for IV infusion.
Study: NCT00349726

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lower volume
Description: 60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo higher volume
Description: 120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
Study: NCT02293356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Injection
Description: patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
Study: NCT03141268

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose breath test
Description: Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose breath test
Description: Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lactulose breath test
Description: Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
Study: NCT02095756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lytera Skin Brightening System (Non-hydroquinone topical therapy)
Study: NCT04295200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling with electrical stimulation
Description: Paravertebral dry needling to L3, 4, 5 multifidi. Electrical stimulation will be applied through the needles for up to 10 minutes total or to the participant's tolerance.
Study: NCT01996891

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Inflammatory Diet
Description: The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-Inflammatory Diet
Description: The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
Study: NCT00240539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
Study: NCT03718702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePain
Description: Electronic pain management programme (ePain)
Study: NCT03152344

Intervention type: PROCEDURE
Intervention: Timed Up and Go
Description: It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value \>12 seconds).
Study: NCT03219931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve BR03 and Bifidobacterium breve B632
Description: This is the active product containing 108 viable cells/strain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve BR03 and Bifidobacterium breve B632
Description: This is the active product containing 108 viable cells/strain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This is the placebo product containing a similar product without bifidobacterium inside.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: This is the placebo product containing a similar product without bifidobacterium inside.
Study: NCT01007747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geranium oil
Description: Daily topical application over neuropathic pain
Study: NCT03185013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: 1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroporation (EP)
Description: Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
Study: NCT03185013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroporation (EP)
Description: Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
Study: NCT01829087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04453098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-week residential program based on a tryptic (diet,
Description: 3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-week residential program based on a tryptic (diet,
Description: 3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3-week residential program based on a tryptic (diet,
Description: 3-week residential program based on a tryptic (diet, exercise, education). The three weeks intervention was followed by a 1-year at-home follow-up.~In the original protocol, participants were involved in a 3-week residential program based on a tryptic (diet, exercise, education).
Study: NCT02310282

Intervention type: DEVICE
Intervention: Telemedicine
Description: In-hospital telemedicine
Study: NCT03642782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroretinogram Pattern (Diopsys® NOVA System)
Description: it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
Study: NCT00650442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal System Placebo - Alternate Adhesive
Description: single application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Transdermal System Placebo - Current Adhesive
Description: single application
Study: NCT03394755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Description: Freeze-dried platelets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Description: Freeze-dried platelets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thrombosomes
Description: Freeze-dried platelets
Study: NCT00073021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol 800 mg (mesalamine)
Description: tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol 400 mg (mesalamine)
Description: tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
Study: NCT03819621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRISS Medical Technologies mediGrid app
Description: IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
Study: NCT01398943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Description: single dose = 5 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH4)
Description: single dose = 5 mg/kg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant Cocktail
Description: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
Study: NCT01414049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Description: Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Description: CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
Study: NCT01121341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein harvesting
Description: Endoscopic versus conventional vein harvesting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein harvesting
Description: Endoscopic versus conventional vein harvesting